Cargando…

Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases

OBJECTIVE: The aim of this study was to analyse the survival impact of primary tumor nodal status (N0/N+) in patients with resectable colorectal liver metastases (CLM), and to determine the value of circulating and disseminated tumor cells (CTCs/DTCs) in this setting. METHODS: In this prospective st...

Descripción completa

Detalles Bibliográficos
Autores principales: Seeberg, Lars Thomas, Brunborg, Cathrine, Waage, Anne, Hugenschmidt, Harald, Renolen, Anne, Stav, Ingunn, Bjørnbeth, Bjørn A., Borgen, Elin, Naume, Bjørn, Brudvik, Kristoffer W., Wiedswang, Gro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491630/
https://www.ncbi.nlm.nih.gov/pubmed/28258416
http://dx.doi.org/10.1245/s10434-017-5818-2
_version_ 1783247171385032704
author Seeberg, Lars Thomas
Brunborg, Cathrine
Waage, Anne
Hugenschmidt, Harald
Renolen, Anne
Stav, Ingunn
Bjørnbeth, Bjørn A.
Borgen, Elin
Naume, Bjørn
Brudvik, Kristoffer W.
Wiedswang, Gro
author_facet Seeberg, Lars Thomas
Brunborg, Cathrine
Waage, Anne
Hugenschmidt, Harald
Renolen, Anne
Stav, Ingunn
Bjørnbeth, Bjørn A.
Borgen, Elin
Naume, Bjørn
Brudvik, Kristoffer W.
Wiedswang, Gro
author_sort Seeberg, Lars Thomas
collection PubMed
description OBJECTIVE: The aim of this study was to analyse the survival impact of primary tumor nodal status (N0/N+) in patients with resectable colorectal liver metastases (CLM), and to determine the value of circulating and disseminated tumor cells (CTCs/DTCs) in this setting. METHODS: In this prospective study of patients undergoing resection of CLM from 2008 to 2011, peripheral blood was analyzed for CTCs using the CellSearch System(®), and bone marrow was sampled for DTC analyses just prior to hepatic resection. The presence of one or more tumor cells was scored as CTC/DTC-positive. Following resection of the primary tumor, the lymph nodes (LNs) were examined by routine histopathological examination. RESULTS: A total of 140 patients were included in this study; 38 patients (27.1%) were negative at the primary colorectal LN examination (N0). CTCs were detected in 12.1% of all patients; 5.3% of patients in the N0 group and 14.7% of patients in the LN-positive (N+) group (p = 0.156), with the LN-positive group (N+) consisting of both N1 and N2 patients. There was a significant difference in recurrence-free survival (RFS) when analysing the N0 group versus the N+ group (p = 0.007) and CTC-positive versus CTC-negative patients (p = 0.029). In multivariate analysis, CTC positivity was also significantly associated with impaired overall survival (OS) [p = 0.05], whereas DTC positivity was not associated with survival. CONCLUSION: In this cohort of resectable CLM patients, 27% had primary N0 colorectal cancer. Assessment of CTC in addition to nodal status may contribute to improved classification of patients into high- and low-risk groups, which has the potential to guide and improve treatment strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1245/s10434-017-5818-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5491630
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-54916302017-07-13 Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases Seeberg, Lars Thomas Brunborg, Cathrine Waage, Anne Hugenschmidt, Harald Renolen, Anne Stav, Ingunn Bjørnbeth, Bjørn A. Borgen, Elin Naume, Bjørn Brudvik, Kristoffer W. Wiedswang, Gro Ann Surg Oncol Colorectal Cancer OBJECTIVE: The aim of this study was to analyse the survival impact of primary tumor nodal status (N0/N+) in patients with resectable colorectal liver metastases (CLM), and to determine the value of circulating and disseminated tumor cells (CTCs/DTCs) in this setting. METHODS: In this prospective study of patients undergoing resection of CLM from 2008 to 2011, peripheral blood was analyzed for CTCs using the CellSearch System(®), and bone marrow was sampled for DTC analyses just prior to hepatic resection. The presence of one or more tumor cells was scored as CTC/DTC-positive. Following resection of the primary tumor, the lymph nodes (LNs) were examined by routine histopathological examination. RESULTS: A total of 140 patients were included in this study; 38 patients (27.1%) were negative at the primary colorectal LN examination (N0). CTCs were detected in 12.1% of all patients; 5.3% of patients in the N0 group and 14.7% of patients in the LN-positive (N+) group (p = 0.156), with the LN-positive group (N+) consisting of both N1 and N2 patients. There was a significant difference in recurrence-free survival (RFS) when analysing the N0 group versus the N+ group (p = 0.007) and CTC-positive versus CTC-negative patients (p = 0.029). In multivariate analysis, CTC positivity was also significantly associated with impaired overall survival (OS) [p = 0.05], whereas DTC positivity was not associated with survival. CONCLUSION: In this cohort of resectable CLM patients, 27% had primary N0 colorectal cancer. Assessment of CTC in addition to nodal status may contribute to improved classification of patients into high- and low-risk groups, which has the potential to guide and improve treatment strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1245/s10434-017-5818-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-03-03 2017 /pmc/articles/PMC5491630/ /pubmed/28258416 http://dx.doi.org/10.1245/s10434-017-5818-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Colorectal Cancer
Seeberg, Lars Thomas
Brunborg, Cathrine
Waage, Anne
Hugenschmidt, Harald
Renolen, Anne
Stav, Ingunn
Bjørnbeth, Bjørn A.
Borgen, Elin
Naume, Bjørn
Brudvik, Kristoffer W.
Wiedswang, Gro
Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
title Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
title_full Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
title_fullStr Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
title_full_unstemmed Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
title_short Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
title_sort survival impact of primary tumor lymph node status and circulating tumor cells in patients with colorectal liver metastases
topic Colorectal Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491630/
https://www.ncbi.nlm.nih.gov/pubmed/28258416
http://dx.doi.org/10.1245/s10434-017-5818-2
work_keys_str_mv AT seeberglarsthomas survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT brunborgcathrine survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT waageanne survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT hugenschmidtharald survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT renolenanne survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT stavingunn survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT bjørnbethbjørna survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT borgenelin survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT naumebjørn survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT brudvikkristofferw survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases
AT wiedswanggro survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases